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ABSTRACT
An effective prophylactic hepatitis B virus (HBV) vaccine has long been available but is ineffective for
chronic infection. The primary cause of chronic hepatitis B (CHB) and greatest impediment for
a therapeutic vaccine is the direct and indirect effects of immune tolerance to HBV antigens. The
resulting defective CD4+/CD8+ T cell response, poor cytokine production, insufficient neutralizing anti-
body (nAb) and poor response to HBsAg vaccination characterize CHB infection. The objective of this
study was to develop virus-like-particles (VLPs) that elicit nAb to prevent viral spread and prime CD4+/
CD8+ T cells to eradicate intracellular HBV. Eight neutralizing B cell epitopes from the envelope PreS1
region were consolidated onto a species-variant of the HBV core protein, the woodchuck hepatitis core
antigen (WHcAg). PreS1-specific B cell epitopes were chosen because of preferential expression on HBV
virions. Because WHcAg and HBcAg are not crossreactive at the B cell level and only partially cross-
reactive at the CD4+/CD8+ T cell level, CD4+ T cells specific for WHcAg-unique T cell sites can provide
cognate T-B cell help for anti-PreS1 Ab production that is not curtailed by immune tolerance.
Immunization of immune tolerant HBV transgenic (Tg) mice with PreS1-WHc VLPs elicited levels of
high titer anti-PreS1 nAbs equivalent to wildtype mice. Passive transfer of PreS1 nAbs into human-liver
chimeric mice prevented acute infection and cleared serum HBV from mice previously infected with HBV
in a model of CHB. At the T cell level, PreS1-WHc VLPs and hybrid WHcAg/HBcAg DNA immunogens
elicited HBcAg-specific CD4+ Th and CD8+ CTL responses.
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Introduction
According to the Centers for Disease Control and Prevention
(CDC), there are 1.2 million carriers of HBV in the U.S. and
approximately 240 million worldwide. In contrast to adult
infection, neonatal HBV infection is rarely cleared and as
many as 90% of perinatally infected children become chroni-
cally infected.1 Vertical transmission of HBV is the major
source of chronic infection in endemic areas, creating a cycle
of perinatal infection, chronicity, and late-term complications
including fibrosis and hepatocellular carcinoma (HCC) with
over 1 million deaths annually. The large number of HBV
chronic carriers represents a significant health problem since
they serve as a reservoir for further infection as well as being at
risk for the development of HCC. Therefore, in addition to
worldwide vaccine programs to prevent new infections, meth-
ods for treating HBV chronic carriers will be necessary to
eradicate this disease. Although a number of nucleotide and
nucleoside analogs are quite effective at reducing HBV viral
load, treatment is associated with poor-sustained responses.
Use of immunomodulatory-pegylated interferon alfa-2b, alone
or in combination with antiviral drugs, is resulting in improved
rates of sustained response but is still less than 30%.2 It has
been hoped that antiviral treatments would permit the immune
system to “reset” allowing for innate/adaptive immunity to
recover. However, this approach has been only marginally
successful at restoring immunity. One consequence of the
standard antiviral therapies is that reduced HBV replication
and antigenic loads deprive the immune system of necessary
antigenic stimuli. Therefore, therapeutic vaccination would
compliment antiviral therapy by providing the necessary
immunogenic stimulus to drive innate/adaptive immune
responses. Because resolution of CHB infection has been
achieved through bone marrow transplantation, vaccine-based
immunotherapy is highly promising, especially in combination
with antiviral drugs.
Although a safe and efficacious preventative vaccine for
HBV has been available for 30 years, it is not effective against
chronic infection. The primary cause of CHB infection and
the greatest impediment to developing a therapeutic vaccine is
the direct and indirect effects of T and B cell immune toler-
ance mediated primarily by secreted HBeAg and HBsAg.3–14
The resulting defective CTL responses, poor cytokine produc-
tion, insufficient nAb levels and non-response to conventional
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HBsAg vaccination (a direct measure of immune tolerance)
characterize CHB infection. The current HBV treatments
(nucleoside analogs and INFalpha) can achieve a “functional
cure”, defined as sustained, undetectable HBsAg and HBV
DNA in serum with or without seroconversion to anti-HBs
after completion of a finite course of treatment with persistent
low levels of covalently closed circular DNA (cccDNA).15
A “complete cure” will require cccDNA clearance from all
hepatocytes and immune restoration to maintain it.
The objective of this study was to develop dual-purpose virus-
like particles (VLPs) to elicit and enhance PreS1-specific nAb
production to prevent viral spread and secondly to primeHBcAg-
specific CD4+/CD8+ T cells to eradicate intracellular HBV and
prevent accumulation of cccDNA.5,16 A number of therapeutic
vaccine clinical trials have been conducted using the HBV envel-
ope antigens (i.e., HBsAg, PreS2 and PreS1-containing subviral
particles) singly or combined, delivered as proteins in adjuvant or
as DNA constructs, all with rather disappointing results.2,17,18 In
many of these studies, antiviral drugs were also used in order to
inhibit viral replication. Nevertheless, the HBV envelope vaccines
to date have not demonstrated clear clinical efficacy. Most, if not
all, previous therapeutic vaccine strategies utilized HBV-derived
antigens or DNA constructs, which are not sufficiently immuno-
genic in patients who have high viral and antigen loads and are
immune tolerant.17,18 In our view, the primary immune defect in
CHB infection is the absence and/or dysfunction of high avidity
HBV-specific Th cells due to immune tolerance mechanisms
including clonal deletion, clonal anergy, clonal ignorance, Treg,
clonal exhaustion and upregulation of inhibitory molecules such
as PD-1, CTLA-4, TIM-3, etc.3–5,8-10,19,20 In order to circumvent
the direct and indirect effects of immune tolerance, chimeric VLPs
were constructed consisting of eight HBV envelope, PreS1-
specific, neutralizing B cell epitopes inserted onto the species-
variant WHcAg, which is approximately 66-68% homologous
with the HBcAg (Figure 1). PreS1-specific B cell epitopes were
chosen because of the viral neutralizing capacity of PreS1 anti-
bodies, the correlation between anti-PreS1 Ab production and
viral clearance, the sequential nature of the PreS1 epitopes and
the preferential expression of PreS1 onHBV virions as opposed to
the much more abundant subviral particles, which can “adsorb
out” anti-HBs antibodies.21–26 TheWHcAgwas chosen because of
the capacity to enhance multivalent (i.e., 240 monomers/VLP) Ab
production and demonstrated efficacy as a vaccine carrier,27,28
and importantly for this application, WHcAg is not crossreactive
at the B cell level with the HBcAg and only partially cross-reactive
at the CD4+/CD8+ T cell levels.29–31 Therefore, CD4+ T cells
specific for foreign, WHcAg-unique T cell sites (i.e., heterospeci-
fic) can provide cognate Th-B cell help for anti-PreS1 antibody
production that is not compromised by immune tolerance as
opposed to the dysfunctional HBV-specific CD4+ T cells (homo-
specific) present in chronic HBV carriers (see Figures 1 and 2).32
The use of Hepatitis B immune globulin (HBIG) in preventing
neonatal infection and in HBV-associated liver transplantation
demonstrates the importance of anti-envelope nAbs, which act as
viral entry inhibitors to prevent hepatocyte-to-hepatocyte viral
infection. Other important roles for nAbs in chronic HBV infec-
tion include: (1) clearing serum HBV, which may reduce T cell
exhaustion mechanisms;33 (2) immune complexes mediate
ADCC and other Fc-mediated effector responses;34,35 (3) nAbs
reduce the risk of viral reactivation;36 (4) nAbs reduce the accu-
mulation of HBV cccDNA by preventing viral spread;16 (5) nAb
may prevent CTL escapemutants from surviving in the periphery;
and (6) may allow safe withdrawal of antiviral drugs “under the
cover” of nAbs. Recent studies have demonstrated the value of
anti-PreS1 antibodies in the clearance of “CHB infection” in
animal models.34,37 An alternative technology, which consists of
injecting a PreS1 peptide (Myrcludex B),16 also functions as a viral
entry-inhibitor but is not as cost-efficient or practical as
Figure 1. Therapeutic HBV Vaccine Design. Eight PreS1 B cell epitopes were inserted onto hybrid WHc-VLPs to elicit neutralizing antibodies and hybrid WHcAg/
HBcAg VLP constructs were used to elicit HBcAg-specific CTL.
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vaccination and injected peptide will not mediate many of the
functions of nAbs listed above. However, Myrcludex B treatment
does reduce the accumulation of HBV cccDNA in humanized
mice, presumably by preventing cell-to-cell viral spread and has
shown clinical efficacy against hepatitis delta virus (HDV)
infection.16,38
Complete recovery from acute HBV infection requires
cellular immune responses, especially multispecific, polyclonal
CTL responses.39 Further, patients with chronic HBV who
experience remission also demonstrate CTL and Th1
responses.40 In contrast, the CTL and Th responses are unde-
tectable or very weak in patients with ongoing chronic
infection.19,20 Therefore, we designed DNA constructs capable
of circumventing immune tolerance at the level of T cell help
for CTL by taking advantage of the same technology used to
bypass poor T cell help for anti-PreS1 Ab production.
Coexpression of the HBcAg linked with the WHcAg in
DNA vectors allows the foreign Th epitopes on WHcAg to
elicit “heterospecific” T cell help for HBcAg-specific CTL,
which can be “helpless” in the context of chronic HBV infec-
tion (Figure 1). As shown in Figure 2, absent or defective (i.e.,
PD-1+) HBcAg-specific “homospecific” Th cells can be sub-
stituted for by WHcAg- “heterospecific” Th cells as long as
the WHcAg-specific Th cell epitopes are physically linked to
the HBcAg-specific CTL epitopes within the same VLP in
order to ensure that both are taken up by the same dendritic
cell (DC) or antigen-presenting cell (APC). T cell help for
CTL function is not mediated directly by Th-CTL interaction
as exists in the direct Th-B cell interaction. T cell help for
CTLs is mediated indirectly through activation of DCs or
other APC; therefore, the concept of “heterospecific” T cell
help for CTL function has not been exploited to the same
degree as in conjugate T-B epitope vaccines, except for a few
examples primarily in tumor vaccinology. Tumor antigen
”homospecific” Th cells are often absent or dysfunctional
due to tolerance mechanisms and experimental tumor vac-
cines that provide heterospecific Th cells have shown
enhanced in vivo antitumor activity.41–44 These precedents
suggest that Th cell defects in chronic viral diseases may
also be circumvented by “heterospecific” Th cells.
As illustrated in Figure 2, immunization with DNA encoding
hybrid WHcAg/HBcAg VLPs will allow DC to present or cross-
present foreign, WHcAg Th cell epitopes in the context of MHC
class II molecules to CD4+ WHcAg-heterospecific Th cells and
the same, now-activated, DCs will present the linked HBcAg-
specific CTL epitopes in the context of MHC class I molecules to
CD8+, HBcAg-specific CTLs. Therefore, the licensing or activa-
tion of the DC can occur in the absence of homospecific T cell
help. Additional advantages to the use of the WHcAg as a carrier
for HBV-specific B cell and CTL epitopes are: (1) in addition to
possessing foreign, WHcAg-unique CD4+/CD8+ T cell epitopes,
WHcAg and HBcAg share conserved epitopes which allows
priming of WHcAg/HBcAg crossreactive CD4+ and CD8+
T cells in addition to heterospecific Th cells; (2) the WHcAg
encapsidates a TLR7 ligand, which serves as an additional co-
stimulus for B cells and DC APC;45 and (3) the particulate
structure of WHcAg enhances B cell/DC antigen uptake.
The studies described herein demonstrated that immuniza-
tion with PreS1-WHc VLPs elicited levels of high titer anti-
PreS1 nAbs in immune tolerant HBV-Tg mice equivalent to
wildtype mice. Further, passive transfer of PreS1-specific
nAbs into human-liver chimeric mice prevented acute infec-
tion and cleared serum HBV from mice previously infected
with HBV (i.e., a model of CHB). At the T cell level, PreS1-
WHc VLPs and hybrid WHcAg/HBcAg DNA immunogens
elicited HBcAg-specific CD4+ Th and CD8+ CTL responses
necessary for clearance of intracellular HBV.
Materials & methods
Mice
Inbred C57BL/6 (B6) (H-2b), C57BL/10 (B10) (H-2b), B6/
BALBc (H-2bxd) mice and B10, TLR7-KO mice were obtained
from the Jackson Laboratory. B10-Tg mice with intrahepatic
expression of the HBcAg protein (HBc-Tg, 0.2 to 2 μg/g liver
protein) or the HBeAg protein (HBe-Tg, 4 to 10 μg/ml serum)
were obtained from Dr. J Ou (USC).46,47 The HBV-Tg mice
(1.3.32) were obtained from F. Chisari (TSRI).48 PreS1-Tg mice
(lineage 107–5) were provided by F. Chisari and L. Guidotti
(TSRI).49
Figure 2. Cellular pathways for the presentation of PreS1-WHc VLPs and hybrid WHcAg/HBcAg DNA. The therapeutic vaccine utilizes the WHcAg as a carrier of HBs-
PreS1 B cell and HBcAg-specific CTL epitopes, which provides “heterospecific” T cell helper function. The absent or dysfunctional HBV-specific CD4+ Th cell
population is represented by the small broken circle showing over-expression of the inhibitory PD-1 molecule. A VLP prime/DNA boost strategy is envisioned.
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Recombinant WHcAg hybrid VLP construction
TheWHcAg and hybridWHcAgVLPs were expressed from the pUC-
WHcAg vector expressing the full-length WHcAg protein codon opti-
mized for expression in E. coli. The sequence for WHcAg (accession
NC_004177) was cloned into the pUC19 vector. For inserting hetero-
logous B cell epitopes, EcoRI-XhoI restriction sites were engineered into
the open reading frame between amino acids 78 and 79 of the core
protein gene. The engineered restriction sites add aGly-Ile-Leu linker on
theN-terminal sideandaLeu linkerontheC-terminal sideof the inserted
epitopes. For VLP-1.6 the heterologous B cell epitope was directly fused
between amino acids 78 and 79 by the polymerase chain reaction using
overlapping primers. The PreS1 sequences and numbering are based on
HBV genotype D, serotype ayw (Accession X65259):MGQNLSTSNP
LGFFPDHQLDPAFRANTANPDWDFNPNKDTWPDANKVGAG
AFGLGFTPPH GGLLGWSPQA QGILHTVPAN PPPASTNRQS
GRQPTPLSPP LRNTHPQA. For fusing the heterologous T950-969
T cell epitope, the AvaI restriction site was used in the HyW VLP
previously described.50 Epitopes were cloned into the VLP gene using
synthetic oligonucleotides comprising the desired epitope coding
sequence and the appropriate engineered restriction sites or overlapping
primers. All WHcAg constructs were transformed into Alpha-Select
competentE.coli (BiolineUSA,Inc.)andconfirmedbyDNAsequencing.
The VLP constructs delivered as DNA were codon opti-
mized for mammals and cloned into pVAX1, grown in Alpha-
Select cells and plasmid purified by the ZymoPure II
MaxiPrep kit (D4202, Zymo Research) according to the man-
ufacturer’s instructions. DNA was formulated in PBS and
concentration was determined spectrophotometrically.
Purified proteins, synthetic peptides, and mabs
The VLP particles were expressed in Alpha-Select E. coli cells
grown in Terrific Broth (Fisher BP2468). Cells were lysed by
passage through an EmulsiFlex-C3 (Avestin, Ottawa, ON,
Canada) and the lysate heated to 65°C for approximately 10
min, then clarified by centrifugation. The WHcAg particles
were selectively precipitated by the addition of solid ammonium
sulfate up to approximately 45% saturation (277 g/L) and the
precipitates were collected by centrifugation. Precipitated VLPs
were redissolved in minimum buffer (10 mM Tris, pH 8), dia-
lyzed against the same buffer and applied to a Sepharose CL4B
column (5x100 cm) or ultrafiltered by tangential flow using
a WaterSep Discover 12, 750K molecular weight cutoff. Finally,
VLPs were formulated in 20 mM Tris, pH8, 100 mM NaCl,
0.5 mM EDTA. Endotoxin was removed from the core prepara-
tions by phase separation with Triton X-114.50,51 The purified
VLPs were 0.2 um sterile-filtered, characterized and aliquoted.
Characterization typically includes custom ELISA, native agarose
gel electrophoresis PAGE, heat stability, circular dichroism and
dynamic light scattering as previously described.50
To produce rPreS1 + 2 andmyr-PreS1 + 2, the gene encoding
ayw preS1S2 (aa1-163) fused to a six-histidine tag was cloned
alone or together with the yeast N-methyltransferase one gene
into the pET Duet vector and transformed into HMS174(DE3)
E coli. Bacteria were grown on LBmedium supplemented with 2
g/l glucose, at 30°C, until the A600 was between 0.6 and 0.8. In
the case of the dual expression cells, the medium was then
supplemented with 10 ml of 5 mM myristic acid in 0.6 mM
BSA in water. At this time 100 mg of IPTGwas added per liter of
culture, and the bacteria allowed to continue to grow for 3–4
h. Bacteria were collected by centrifugation and stored frozen
until processed. Bacterial pellets were suspended in 6M urea and
disrupted by a single passage through an Avestin Emulsiflex C3
operating at a pressure of 25000 psi. The use of urea was to
prevent the rapid proteolysis of the soluble protein upon disrup-
tion of the bacteria. The lysate was clarified by centrifugation and
applied to a nickel column (BioRad), extensively washed with
6Murea until the absorbance at 280 nmhad returned to baseline
values then washed with water to remove the urea. The protein
was eluted using 50 mM citric acid and dialyzed against 10 mM
acetate buffer pH 5.0.
Synthetic peptides were synthesized by and purchased from
Eton Biosciences (San Diego, CA) and Abclonal (Woburn, MA).
PreS1-specific Mab 18/7 was provided by W. Gerlich
(Justus Liebig University Giessen). PreS1-specific Mabs AP-2
and KR-127 were purchased from Santa Cruz Biotechnology
(Dallas, TX). PreS1-specific Mab Ab001 was purchased from
Beacle, Inc. (Okayama, Japan).
Human-liver chimeric mice
Homozygous NRG-fumarylacetoacetate hydrolase (fah/
fah) mutant mice (NRG/F) were maintained with 8 μg/
ml 2-(2-nitro-4-fluromethylbenzoyl)-1,3 cyclohexanedine
(NTBC).52 Anesthetized mice were injected in the spleen
with 1 × 106 human primary hepatocytes (Triangle
Research Laboratories, NC). After transplantation, the
NRG/F-hu mice were subjected to three rounds of
NTBC drug recycling to eliminate mouse hepatocytes
and to provide space for human hepatocyte growth.
Thereafter, mice were infected with 1 × 106 GE copies
of HBV/genotype C (isolated from HBV-infected human-
liver chimeric mouse serum) injected retro-orbitally.
Human albumin in mouse sera was measured with
a modified ELISA method (Bethyl Labs Human Albumin
ELISA Quantitation Set).53
Passive transfer of antisera
Anti-PreS1-WHc VLP sera (0.2 ml) or control anti-WHc sera
(0.2 ml) were injected i.v. into human-liver chimeric mice prior
to infection with 1 × 106 GE copies of HBV per mouse in the
control and acute groups. For the chronic group, 0.2 ml of anti-
PreS1-WHc VLP sera were injected i.v. 2 and 5 weeks after HBV
infection. TomeasureHBVDNA, sera were collected from the tail
vein and HBV DNA was extracted with QIAampMinElute Virus
Spin Kit according to the manufacturer’s instructions. Primer 1
(HBV2270F: 5ʹ-GAGTGTGGATTCGCACTCC-3ʹ) and Primer 2
(HBV2392R: 5ʹ-GAGGCGAGGGAGTTCTTCT-3ʹ) were used in
the Q-PCR reaction to measure HBVDNA. A human serumwith
known viral titer was used as an HBV DNA standard.53
Virus neutralization assay
Neutralization was assessed as previously described.54 Briefly,
HDV (HBV genotype D, L/M/S -HBsAg subtype ayw) parti-
cles were derived from the culture medium from transfected
cells and suspended at 1 × 109 particles per ml. One hundred
microliter of HDV-HBV particles were mixed with 100 μl of
sample (sera or purified Mab neat, 1/10 and 1/100 dilutions in
PBS) and incubated at 37°C for 1 hr such that final dilutions
of sera were 1:40, 1:400 and 1:4000 and Mab was 5, 0.5, and
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0.05 μg. The mix was adjusted to 5% PEG and inoculated on
HepaRG (106 cells for a multiplicity of infection of 100 viral
particles per hepatocyte). After 16 hr, the inoculum was
removed and replaced with fresh medium. Cells were har-
vested at day 7 post inoculation for the detection of intracel-
lular genomic HDV RNA as a marker of infection by
Northern Blot and quantified by densitometry.
Immunizations and serology
Groups of mice were immunized intraperitoneally (i.p.) with the
PreS1-WHc VLPs (usually 10–20 μg) emulsified in incomplete
Freund’s adjuvant (IFA) for both antibody production and T cell
experiments. DNA immunization was performed i.m. in the
tibialis cranialis muscle with 50 μg pVAX-VLP-1.6 plasmid in
a volume of 50 μl. Immediately after immunization, the muscle
was electroporated (EP) using Clinporator 2 device (IGEA,
Carpi, Italy) with a pulse pattern of one 1 ms 600 V/cm pulse
followed by a 400 mg 60 V/cm pulse. A booster dose was given 1
month later and mice were sacrificed 2 weeks thereafter. For
antibody experiments, mice were bled retro-orbitally and sera
pooled from each group. Periodically individual mouse sera were
tested to confirm the fidelity of the pooled sera results. Anti-
WHc and anti-insert IgG antibodies were measured in murine
sera by an indirect solid-phase ELISA by using the homologous
WHcAg (50 ng/well), HBV virions, rPreS1 + 2, or synthetic
peptides (0.5 μg/well), representing the inserted PreS1
sequences, as solid-phase ligands as described previously.55
Serial dilutions of both test sera and preimmunization sera
were made and the data are expressed as antibody titers repre-
senting the reciprocals of the highest dilutions of sera required to
yield an optical density at 492 nm (OD 492) three times an equal
dilution of preimmunization sera.
In vitro T cell cytokine assays
Spleen cells from groups of three mice each of the various
lineages were harvested and pooled 4–6 weeks after immuniza-
tion with the PreS1-WHc VLPs. Spleen cells (5 × 105) were
cultured with varying concentrations of WHcAg, HBcAg or
synthetic peptides derived from the WHcAg, HBcAg or PreS
region. For cytokine assays, culture supernatants were harvested
at 48 h for IL-2 determination and at 96 h for interferon-gamma
(IFNγ) determination by ELISA. IFNγ productionwasmeasured
by a two-site ELISA using mAb 170 and a polyclonal goat anti-
mouse IFNγ (Genzyme Corp., Boston, MA).
Results
Construction of PreS1-WHc VLPs
The HBV encodes three envelope proteins termed small (HBs),
middle (M) and large (L) proteins, which share the C-terminal
HBsAg domain. The M and L proteins carry additional
N-terminal extensions of 55aa (PreS2 region) and 108 or 119aa
depending on genotype (PreS1 region). The 1-108aa (genotype D)
PreS1 sequence numeration is used throughout. The stoichio-
metric ratio of L/M/HBs proteins inHBV virions is approximately
1:1:4, whereas the most abundant secreted small noninfectious
subviral particles contain almost exclusively the small HBsAg
protein, lesser amounts of PreS2 and only trace amounts of the
PreS1 region.56 Therefore, for a therapeuticHBV vaccine designed
to elicit HBV virus-specific antibodies, inclusion of PreS B cell
epitopes is imperative. Antibodies produced to the HBsAg
domain can be “adsorbed-out” by subviral HBsAg particles that
circulate at levels as high as 1.0 mg/ml in chronic HBV sera.
A second imperative is that the PreS B cell epitopes chosen must
elicit HBV-specific nAbs. A number of PreS1-specific B cell epi-
topes have been identified in mice by immunization with HBsAg/
L particles, PreS1-derived synthetic peptides and by serological
analysis of human HBV-infected blood samples (i.e., 1–21, 21–47
and 83–106).55,57 Further, in vitro neutralization studies and
in vivo immunization studies with PreS1 epitope-specific synthetic
peptides demonstrated that PreS1-specific antibodies could pro-
tect chimpanzees from experimental HBV challenge in the
absence of anti-HBs region antibody.21–23 Subsequently, several
groups delineated the PreS1 residues (aa 9–18) and (aa28-48)
involved in HBV-hepatocyte receptor recognition.58–60
Based on these earlier studies, we initially chose four PreS1
B cell epitopes (1.1, 1.2, 1.3 and 1.4; see Table 1) for insertion
onto the exposed loop region of the WHcAg platform. Four
PreS1-WHc VLPs were selected from a larger library based on
assembly, yield and antigenicity determined by binding to
a series of PreS1-specific monoclonal antibodies (Mabs). The
inserted PreS1 sequences were modified in a second set of
VLPs designated 1.1+, 1.3+, 1.4+ and 1.5 in order to broaden
recognition by the panel of PreS1-specific Mabs. As shown in
Table 1, purified HBV virions, recombinant (r) PreS1/PreS2
protein and myristoylated rPreS1/PreS2 protein were recognized
by all four PreS1-specific Mabs and an anti-PreS1 peptide (aa83-
106) polyclonal antisera. Note that Mab Ab001, which binds aa1-
15 is not blocked by myristoylation as previously suggested,
which indicates heterogenicity in the Ab response to the PreS1
amino terminus.61 The PreS1-specific Mab binding profiles for
the selected PreS1-WHc VLPs and a series of synthetic peptides
demonstrated that the inserted PreS1 sequences were accessible
on the surface of the VLPs and appropriately antigenic. Based on
antigenicity and immunogenicity data, we consolidated the
inserted PreS1 sequences from VLP-1.1+ and VLP-1.4+ into
the loop region of a single VLP (1.6). We also consolidated the
PreS1 sequences from VLP1.3+ (inserted into the WHcAg loop)
and VLP1.2 (fused to the N-terminus of the WHcAg) onto
a single VLP (1.9). Note that the combination of VLPs 1.6 +
1.9 is efficiently bound by all four PreS1-specific Mabs and the
anti-aa83-106 antisera in a solid-phase ELISA format (Table 1).
Immunogenicity of PreS1-WHc VLPs
Each PreS1-WHc VLP was analyzed for immunogenicity and
anti-PreS1 Ab fine specificity by injecting groups of B10 mice
each with 20 μg and boosting with 10 μg of VLP formulated in
incomplete Freund’s adjuvant (IFA) (Table 2). All VLPs elicited
anti-PreS1 IgG endpoint titers of at least 1:625,000 after a boost
measured on rPreS1/2 protein and the titers ranged between
1:125,000 and 1:6x106 (i.e., VLP1.6) as measured on purified
HBV virions demonstrating the relevance of the anti-PreS1 Ab
response to the virus. The fine specificity of the anti-PreS1 Abs
correlated well with the PreS1 sequences inserted on the VLPs.
For example, VLP-1.2 elicited Abs specific for only aa83-106,
the inserted sequence; and VLP-1.3 elicited Abs specific for the
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aa1-15 insert. Further, fine specificity mapping of the anti-VLP
antisera on a large panel of PreS1 peptides (see Table 3)
revealed that the PreS1 B cell epitopes segregated into an
N-terminal domain (aa1-21: containing three overlapping epi-
topes, aa1-15, aa5-16 and aa11-21); a central domain (aa20-47:
containing three overlapping epitopes, aa20-23, aa22-32, and
aa30-42); and a C-terminal domain (aa83-106: containing two
epitopes, aa83-94 and aa95-106) revealing at least eight PreS1
epitopes identified by antisera raised against this panel of 10
PreS1-WHc VLPs. Note that VLPs 1.6 and 1.9 elicited
a complementary set of PreS1-specific Abs and combining
these two VLPs for immunization yielded the full spectrum of
anti-PreS1 Ab specificities (Table 3).
Important characteristics of the PreS1-specific Abs elicited by
PreS1-WHc VLPs include the ability to bind native PreS1 epi-
topes expressed on L/M/S-HBsAg particles and to recognize
both major serotypes (i.e., ay and ad). Although the PreS1 region
is highly conserved, especially the receptor binding N-terminal
domain, there are genotype-specific differences. Therefore, anti-
PreS1-WHc VLP murine sera were tested by ELISA for binding
to a panel of solid-phase L/M/S-HBsAg particles purified from
infected patients, representing the two major serotypes (Figure
3). Although the amount of PreS1 sequence among the four L/
M/S-HBsAg preparations varied, Mab 18/7 served as a reference
antibody. Anti-VLPs 1.2, 1.5 and 1.6 Abs each recognized all
four L/M/S-HBsAg particles at varying dilutions, indicating
a high degree of crossreactivity for the major ay and ad sero-
types, especially because all of the inserted PreS1 sequences were
derived from the ay serotype. Although the results indicate it is
probably not necessary to insert genotype-specific PreS1
sequences, if required it can be easily accomplished with this
technology.
Table 1. Antigenicity of PreS1-WHc VLPs.
PreS1-Specific Mabs (Min binding conc. [ng/ml])
Ab001 18/7 AP-2 KR-127 α-p(83–106)
Antigens aa(1–15) aa(20–23) aa(23–34) aa(26–34) aa(83–106)
HBV (virions) 0.5 2.0 25.0 75.0 +
rPreS1 + 2 0.3 0.3 1.6 1.6 +
myr-rPreS1 + 2 0.3 0.3 1.6 1.6 +
PreS1-VLPs
VLP-1.1 (21–43) 0 0 1.6 1.6 0
VLP1.1+ (19–43) 0 0.3 40 1,000 0
VLP-1.2 (83–106) 0 0 0 0 +
VLP-1.3 (1–21) 0.3 0 0 0 0
VLP-1.3+ (1–25) 0.3 1.6 0 0 0
VLP-1.4 (15–31) 0 0.3 0 0 0
VLP-1.4+ (15–34) 0 8.0 8.0 8.0 0
VLP-1.5 (1–34) 0.3 0.3 0 0 0
VLP-1.6 (15–40) 0 0.3 1.6 1.6 0
VLP-1.9 (83-106-NH2/ 1-25-loop) 0.3 1.6 0 0 +
VLPs 1.6 + 1.9 0.3 0.3 1.6 1.6 +
PreS1-Peptides
p(1–15) 20 0 0 0 0
p(5–16) 1.6 0 0 0 0
p(11–21) 0 0 0 0 0
p(18–25) 0 8.0 0 0 0
p(1–36) 0.3 1.6 8.0 1.6 0
p(21–42) 0 0 8.0 1.6 0
p(83–106) 0 0 0 0 +
The depicted panel of antigens (virions, PreS1 + 2 proteins, PreS1-WHc VLPs, and synthetic peptide) were coated on ELISA plates as solid-
phase ligands. Dilutions of PreS1-specific Mabs or polyclonal murine anti-p83-106 were incubated with the solid-phase antigens to
determine binding by ELISA. Binding is expressed as the minimum concentration of mAb to yield 3x the O.D. 492 of an irrelevant Mab.
Binding by the polyclonal anti-p83-106 sera is depicted as titers plus (+) or minus (0) binding. myr-rPreS1 + 2, myristoylated rPreS1 + 2.
Table 2. Immunogenicity and Fine Specificity of Anti-PreS-WHc VLP Sera.
Antibody titer (1/dilution) vs PreS1 Antigens
anti-VLP Sera HBV1 rPreS1± 2 p(1–15) p(18–25) p(1–36) p(21–42) p(83–106)
VLP-1.1 125K2 625K 0 0 625K 3x106 0
VLP-1.1+ 125K 3x106 0 125K 6x106 125K 0
VLP-1.2 625K 625K 0 0 0 0 625K
VLP-1.3 125K 625K 3x106 0 3x106 0 0
VLP-1.3+ 625K 3x106 625K 5K 3x106 0 0
VLP-1.5 125K 625K 50K 10K 2.1x106 50K 0
VLP-1.4 625K 625K 0 100K 1.2x106 5K 0
VLP-1.4+ 3x106 3x106 0 50K 6.4x106 625K 0
Hybrid VLPs
VLP-1.6 6x106 6x106 0 625K 6.4x106 3x106 0
VLP-1.9 125K 1.2x106 125K 5K 625K 0 125K
Groups of three B10 mice each were immunized i.p. (20 µg) and boosted (10 µg) with the indicated PreS1-WHc VLPs (emulsified in IFA). Four weeks post-boost sera
were collected, pooled and binding to a panel of PreS1-specific antigens was determined by solid-phase ELISA. Endpoint titers (1/dilution) are depicted as the
highest serum dilution to yield 3x the OD 492 of equivalent dilutions of normal mouse serum (NMS). 1 HBV = purified virions, 2 K = thousands.
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One characteristic of hepadnavirus core proteins that contri-
butes to enhanced immunogenicity is the presence of a domain at
the C-terminus that incorporates a TLR7 ligand into the
assembled particles.45 To determine the influence of TLR7 signal-
ing on the immunogenicity of PreS1-WHc-VLPs, TLR7-knock
out (KO) mice and wildtype mice were immunized with VLP-1.6
and anti-PreS1 Ab titers were determined three and 5 weeks after
a single injection (Figure 4).Wildtypemice produced significantly
higher endpoint titers of anti-PreS1 Ab at week 3 (1:1.2x106) and
at week 5 (1:15x106) as compared to TLR7-KO mice at week 3
(1:50,000) and week 5 (1:250,000). This result indicates that innate
TLR7 signaling is operative at least during the primary humoral
response to PreS1-WHc VLP immunization.
Ability of PreS1-WHc VLPs to circumvent immune
tolerance
Several investigators have suggested using the HBcAg as
a carrier for PreS protective B cell epitopes in a possible
therapeutic vaccine, which is problematic given immune
tolerance to the HBc/HBeAgs in CHB infection, especially
during the immune tolerant (IT) phase.61,62 As a means of
circumventing immune tolerance, we have utilized the
WHcAg as a carrier of eight PreS1 B cell epitopes.
Immunization of HBeAg-MUP-Tg mice and HBeAg
x HBcAg-MUP double-Tg mice, which are extremely tol-
erant to the HBc/HBeAgs at the Th/CTL levels,63 with the
HBcAg (20ug, IFA) demonstrated a high degree of Th cell
tolerance as reflected by a 900-fold reduction in anti-HBc
antibody as compared to wildtype B10 mice (Figure 5(a))
and a 20-fold reduction in crossreactive anti-WHc Abs.
The low-level anti-HBc Abs in the HBe/HBcAg-Tg mice
reflects the contribution of T cell-independent antibody
production.64 In contrast, immunization of HBeAg-MUP-
Tg or HBe/HBcAg-MUP-Tg mice with a PreS1-WHc VLP
(VLP-1.1) yielded equivalent high titer anti-WHc and,
more importantly, anti-PreS1 Abs compared to wildtype
mice, whereas, crossreactive anti-HBc Ab production was
Table 3. Immunogenicity and fine specificity of the combination of VLP-1.6 and VLP-1.9.
Antibody Titer (1/dilution) vs. PreS1 Antigens
Immunogen WHc rPreS1± 2 p(1–15) p(5–16) p(11–21) p(18–25) p(1–36) p(22–32) p(30–42) p(21–42) p(83–106) HBV (virions)
VLP-1.6 +
VLP-1.9
250K 2x106 57K 34K 32K 0.5K 625K 0.8K 6K 250K 23K 37K
Groups of five mice were immunized once with the combined VLP-1.6 + VLP-1.9 (20 µg each, i.p. in IFA). Three weeks post-immunization sera were collected, pooled
and anti-PreS1 fine specificities determined by ELISA using the panel of antigens depicted as solid-phase ligands. Endpoint Ab titer (1/dilution) was determined by
the highest dilution of sera to yield 3x OD492 of NMS. K = thousands
Figure 3. Anti-PreS1-WHc VLP Abs bind multiple L/M/S-HBsAg particles of both major serotypes (ad/ay). Four L/M/S-HBsAg preparations, either ay or ad, derived
from HBV-infected sera were used as solid-phase ligands to measure anti-PreS1 Ab binding by ELISA. Groups of three mice were immunized (i.p.) with 20 µg and
boosted with 10 µg of the indicated PreS1-WHc VLPs and pooled sera were tested for binding to the panel of L/M/S-HBsAg antigens by ELISA. Endpoint titers (1/
dilution) are shown. The Mab 18/7 was included for reference.
Figure 4. Immunogenicity of PreS1-WHc VLP-1.6 in WT and TLR7-KO Mice. Groups of three WT or TLR7-KO mice were immunized (i.p.) with a single dose of 20ug of
PreS1-WHc VLP-1.6 emulsified in IFA and 3 and 5 weeks later IgG anti-PreS1 endpoint titers were determined on pooled sera by ELISA.
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significantly reduced (25–12.5-fold) (Figure 5(b)).
Similarly, immunization with PreS1-WHc VLPs 1.1+ and
1.2 elicited equivalent high titer anti-PreS1 Abs in HBeAg-
MUP-Tg mice and B10 wild-type mice (data not shown).
Furthermore, HBV-Tg mice, which express the HBsAg S/
M/L envelope antigens as well as the HBe/HBcAgs and are
immune tolerant to the HBV structural antigens,65 were
immunized and boosted with a mixture of 20ug each of
PreS1-WHc VLPs (1.2, 1.3 and 1.6) and anti-PreS1 humoral
responses compared to wildtype mice (Table 4). Anti-PreS1
antibody production in HBV-Tg mice detected by binding to
the rPreS1/2 protein, HBV virions and 3 of 5 PreS1 peptides
was equivalent to or higher than in wildtype mice and lower
against two peptides (aa18-25 and aa83-106), possibly due to
greater adsorption of these anti-PreS1-specific Abs by circu-
lating PreS1 antigen-bearing particles. Similarly, PreS1-Tg
mice immunized and boosted with a combination of VLPs
1.6 and 1.9 produced equivalent or higher titer anti-PreS1 Abs
as compared to wildtype mice with the same exception of
anti-aa18-25 and anti-aa83-106 Abs, again suggesting these
two specificities may be preferentially adsorbed by circulating
PreS1 antigen (Table 4). It is important to note that anti-
PreS1 Ab production did not result in liver injury in either
HBV-Tg or PreS1-Tg mice determined by the lack of serum
ALT elevation (data not shown).
To analyze the Th cell response to PreS1-WHc VLPs,
HBV-Tg and wildtype mice were immunized with either
VLP-1.1+ or VLP-1.3 and splenic IL-2 and IFNγ cytokine
production in response to culture with a panel of recall
antigens was determined (Figure 6). As expected, native
WHcAg was the dominant source of Th cell cytokine pro-
duction in response to PreS1-WHc VLP immunization as
well as the constituent WHcAg-derived peptides W60-80
and W120-140 in both HBV-Tg and wildtype mice. Note
that Th cells crossreactive for the HBcAg were also primed
by immunization with PreS1-WHc VLPs 1.1+ and 1.3 but
produced IL-2 and IFNγ to a lesser degree than in response
to the WHcAg, especially in HBV-Tg mice. However, the
fine specificity of the crossreactive HBcAg-specific T cells
could not be determined in HBV-Tg mice because HBV-Tg
mice on a B6/BALBc background are tolerant to the H120-
140 dominant HBcAg-specific T cell site, unlike wild-type
mice, in which H120-140-specific Th cells were detected.
The W120-140 and H120-140 sequences differ by only two
amino acids. Therefore, WHcAg-specific Th cells are domi-
nant in PreS1-WHc VLP immunized mice, although low-
level HBcAg-crossreactive Th cells are also primed even in
HBV-Tg mice; however, the lack of a H120-140-specific Th
cell response is evidence of HBcAg-specific Th cell tolerance
in HBV-Tg mice.
In summary, the results from immunization studies in
HBe/HBcAg-MUP-Tg mice, HBV-Tg mice, and PreS1-Tg
mice reveal that use of the WHcAg platform to carry PreS1
B cell epitopes is capable of circumventing HBe/HBcAg-
specific and L/M/S-HBsAg-specific Th cell tolerance, which
characterizes CHB infection. It is also notable that the HBV-
Figure 5. Immunization with PreS1-WHc VLP1.1 circumvents immune tolerance in HBe/HBcAg-Tg mice. Groups of three B10 wildtype, B10 HBeAg-Tg, and B10 HBe/
HBcAg double-Tg mice were immunized (i.p.) with a single 20 µg dose of HBcAg (a) or PreS1-WHc VLP1.1 (b) emulsified in IFA. Four weeks after immunization sera
were collected, pooled and tested by ELISA for IgG anti-HBc, anti-WHc, and anti-PreS1 Abs expressed as endpoint (1/dilution) titers.
Table 4. Comparative immunogenicity of PreS1-WHc VLPs in HBV-Tg, PreS1-Tg and Wildtype Mice.
Antibody Titers (1/dilution) vs. PreS1 Antigens
n HBV rPreS1± 2 p(1–15) p(1–36) p(18–25) p(21–42) p(83–106)
Wildtype
(B6/BALB/c)
5 50K 125K 125K 3x106 625K 625K 125K
HBV-Tg
(B6/BALB/c)
5 72K 190K 625K 6x106 50K 875K 0.5K
PreS1-Tg
(B6)
6 110K 2x106 70K 3x106 70K 900K 14K
Groups of five wild-type or HBV-Tg mice were immunized i.p. and boosted with a mix of PreS1-WHc VLPs-1.2, −1.3 and −1.6 (20ug each in IFA). A group of six PreS1-Tg mice
was immunized i.p. and boosted with amix of PreS1-WHc VLPs-1.6 and−1.9. Five weeks after the boost, sera was collected, pooled and binding to a panel of PreS1-specific
antigens was determined by solid-phase ELISA. Endpoint titers (1/dilution) are depicted as the highest serum dliution to yield 3x the OD492 of NMS. K = thousands.
258 D. WHITACRE ET AL.
Tg and PreS1-Tg lineages are not tolerant at the B cell level to
PreS1 B cell epitopes. The presence of PreS1/2-specific as well
as HBsAg-specific IgG in immune complexes in CAH patients
is also consistent with a lack of B cell tolerance during the
immune clearance phases of chronic HBV infection.66
Immunization with Pres1-WHc VLPs elicits HBV
neutralizing antibodies
The previous results indicate that PreS1-WHc VLPs are cap-
able of circumventing Th cell immune tolerance and can elicit
high titer anti-PreS1-specific Abs of at least eight different
specificities. However, to be relevant, the anti-PreS1-specific
Abs produced must be virus-neutralizing (i.e., nAb). As
shown in Figure 7, the anti-PreS1 antibodies elicited by
immunization with six PreS1-WHc VLPs efficiently neutra-
lized/prevented infection of a HepaRG human hepatocyte cell
line by a hepatitis delta virus (HDV) coated with HBV envel-
ope proteins (i.e., L/M/S HBsAg/ay) in an infection assay
developed by Sureau, et al.54 Note that antisera to PreS1-
WHc VLPs 1.4+ and 1.1+ were capable of completely pre-
venting HDV-HBV infection of HepaRG cells even at final
dilutions of 1:4000 as did 0.05 µg/ml of Mab 18/7 (a standard
anti-PreS1 neutralizing Mab). In an attempt to find an end-
point dilution for viral neutralization, a higher stringency
infection was performed (lower panel, Figure 7). In this high
stringency assay Mab 18/7 even at 5.0 μg/ml was not able to
totally neutralize infection; however, the three polyclonal anti-
PreS1-WHc VLP antisera completely neutralized infection at
final dilutions of 1:400 (VLPs 1.1+ and 1.4+) and 1:40 (VLP
1.5). Similarly, anti-PreS1-WHc VLP 1.6 antibody completely
prevented infection at a final dilution of 1:400 (data not
shown).
Anti-PreS1-WHc Abs prevent acute infection and clear
serum HBV in previously infected mice in vivo in
human-liver chimeric mice
In addition to the ability of PreS1-specific Abs to neutralize HBV
infection of a human hepatocyte cell line in vitro (Figure 7), to
determine the efficacy of PreS1-specific nAbs in an infectious
in vivo systemwe utilizedmice made chimeric with human-liver
cells.67,68 Human-liver chimeric mice are immune compro-
mised, so first wildtype mice were immunized with
a combination of VLP-1.6, VLP-1.2 and VLP-1.3 and 0.2 ml of
secondary anti-PreS1 antisera or control anti-WHc sera was
adoptively transferred into human-liver chimeric mice: (1)
prior to HBV infection (acute infection and controls); or (2) 2
weeks after HBV infection (“chronic infection”) with 1 × 106
HBV GE copies/mouse in each challenge. HBV DNA in the
serum was monitored every 2 weeks for 8 weeks and HBV
DNA in the liver was determined at termination at 8 weeks post-
infection (Figure 8). Control mice demonstrated escalating
serum HBV DNA levels that peaked at 6–8 weeks post-
infection. The four mice adoptively transferred with anti-PreS1
Abs prior (day −1) to HBV infection were protected against
acute infection with the exception of one “breakthrough” at 8
weeks post-infection, as nAb levels waned. The acute group only
received a single injection of 0.2 ml of anti-PreS1 sera, while the
chronic group received adoptive transfer of 0.2 ml of anti-PreS1
Figure 6. Analysis of CD4+ Th cell response to PreS1-WHc VLP immunization in HBV-Tg mice. Groups of three HBV-Tg or wildtype (B6/BALBc), mice were immunized
(s.c.) with 20ug of either PreS1-WHc VLP-1.1+ or VLP-1.3 emulsified in IFA. Four weeks later spleen cells were harvested and cultured (5x105) with varying
concentrations of the indicated WHcAg, HBcAg or WHc(W)- or HBc(H)-derived synthetic peptides. Culture supernatants were collected at 48 h for IL-2 determination
and at 96 h for IFNγ determination by 2-site ELISA. The results represent single mice but are representative of three mice/group.
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sera at 2 and 5 weeks after the HBV infection. All chronically
infected mice cleared serumHBVDNA by week 6 post-infection
and remained negative for serum HBV DNA at the termination
of the experiment (Figure 8(a)). At termination, liver HBVDNA
levels were determined and no virus was detected in the livers of
the acute group. Although not statistically significant, the HBV
DNA levels in the livers of the chronic group were somewhat
lower than those in the control group (Figure 8(b)). Anti-PreS1
nAb were not expected to clear the preexisting infection in the
liver and the reducedHBVDNA liver load compared to controls
most likely represents the ability of circulating anti-PreS1 nAbs
to prevent viral spreading to uninfected hepatocytes since HBV
infection requires secretion of cell-free virus. Immunohistology
staining for HBsAg detected significant HBsAg in three of the
four control livers, no HBsAg in the acute livers and HBsAg
staining in only one of six “chronic” livers (Figure 8(c)).
These results provide a proof-of-concept that the PreS1-WHc
VLPs can elicit nAbs capable of preventing an acute HBV infec-
tion into human-liver cells and are sufficient to clear serumHBV
from “chronically infected” mice and may prevent spreading of
HBV amongst human-liver cells in vivo as evidenced by the
decreased HBsAg staining in the chronic group.
WHcAg-based DNA constructs designed to circumvent
immune tolerance and to elicit HBcAg-specific CTL
We demonstrated that immunization with PreS1-WHc VLPs
could elicit noncrossreactive WHcAg-specific heterospecific
CD4+ T cells and to a lesser degree WHcAg/HBcAg cross-
reactive CD4+ T cells that may mediate viral clearance via
cytokine production. For example, immunization with PreS1-
WHc VLP 1.1+ primed HBcAg-crossreactive CD4+ T cells in
both wildtype and HBV-Tg mice (Figure 6). To determine the
ability of the PreS1-WHc VLPs to elicit a CD8+ CTL response
in either a DNA or VLP format, we immunized groups of mice
with either VLP-1.6 protein or DNA encoding VLP-1.6. As
shown in Figure 9(a), the DNA version elicited superior
CD4+ T cell responses to VLP-1.6 and its constituent three
WHc-specific CD4+ T cell epitopes (WHc60-80, WHc 80–95
and WHc120-140) as compared to the protein version of VLP-
1.6. Moreover, the DNA immunogen elicited a strong CD8+
CTL response to WHc10-25 and a cross-reactive CTL response
to the HBcAg-specific HBc93-100 CTL epitope, whereas, pro-
tein VLP-1.6 did not prime CTL responses efficiently.
Therefore, just as crossreactive HBcAg-specific CD4+ T cells
can be primed by PreS1-WHc VLPs (Figure 6), crossreactive
HBcAg-specific CD8 + T cells can be primed by DNA encod-
ing PreS1-WHc VLPs (Figure 9(a)). It is also notable that,
despite the superior priming of WHcAg-specific CD4+ T cells
by the DNA vaccine compared to the VLP protein, the VLP-1.6
protein immunization elicited far superior (at least 10x higher)
anti-WHc and anti-PreS1 Ab responses (Figure 9(b)). This is
a dramatic demonstration of the complementarity between the
two forms of immunization and that the best method to ensure
high titer nAb production as well as effective CTL responses is
to use a VLP prime/DNA boost strategy. These WHcAg/
HBcAg crossreactive CD4+/CD8+ T cells represent only one
method of eliciting HBcAg-specific CD4+/CD8+ T cells. It was
anticipated that the WHcAg-“heterospecific” Th cells primed
by a hybrid WHcAg/HBcAg DNA vaccine would enable the
direct priming of a significantly stronger HBcAg-specific CD8+
CTL response.
Therefore, the goal was to co-express the WHcAg with the
HBcAg in the same VLP in order to allowWHcAg-specific (hetero-
specific) Th cells to provide T cell help for the priming and main-
tenanceofHBcAg-specificCD8+CTLs (seeFigures 1, 2). Because the
WHcAg and the HBcAg are 68% homologous and structurally very
similar it was possible to obtain hybrid WHcAg/HBcAg assembled
VLPs in E. coli using two different strategies. First, full-length
WHcAg188 and truncated HBcAg149 genes were co-expressed in
E. coli to form hybrid WHcAg/HBcAg VLPs. The subunit for
assembly of this VLP is a dimer and biochemical analysis of VLPs
Figure 7. Neutralization of HBV Infection by PreS1-WHc VLP Antisera. Groups of three mice were immunized with the six depicted PreS1-WHc VLPs containing
separate neutralizing B cell epitopes. Mice received a primary (20 μg) and a single booster (10 μg) immunization (i.p., IFA). Antisera were collected after the boost,
pooled and the neutralization activity was determined in an in vitro infection assay using a modified hepatocyte cell line (HepaRG) infected with HDV particles coated
with HBV envelope proteins.54 The bottom panel represents a higher stringency neutralization assay.
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from E. coli co-expressing WHcAg and HBcAg showed that, in
addition to homodimers, there was a significant fraction of mixed
WHcAg/HBcAg dimers, indicating the presence of hybridWHcAg/
HBcAg VLPs (Figure 10(a)). The presence of hybrid WHcAg/
HBcAg VLPs was confirmed by ELISA analysis that utilized
a WHcAg-specific mAb that did not cross-react with HBcAg and
reciprocally an HBcAg-specific mAb that did not cross-react with
WHcAg to capture and/ordetect hybridVLPs in solution (Figure 10,
lower panels). These hybrid-specific ELISAs do not detect either
WHcAg or HBcAg homogeneous particles.
The second method used was to fuse the HBcAg149 gene to the
N-terminus of the WHcAg188 gene with a flexible linker to form
a “single-chain dimer” and to express the one contiguous open
reading frame in E. coli. Again, the biochemical and ELISA analysis
indicated that hybrid WHcAg/HBcAg VLPs were produced and
designated as VLP-347 (Figure 10(b)). The advantage of the single
polypeptide method is that only hybrid VLPs are possible, whereas,
separate expression of the two gene constructs could theoretically
produce a mixture of homologous and hybrid assembled VLPs,
although our results indicate this is not likely in E. coli, at least.
To establish the ability of hybrid WHcAg/HBcAg VLP DNA
constructs to elicit HBcAg-specific CTL, B6mice were immunized
intramuscularly (i.m.) with DNA (100 g, 2 times) encoding VLP-
347, hybrid WHcAg188/HBcAg149 or HBc alone (Figure 11). The
hybrid WHcAg/HBcAg DNA construct elicited equal or superior
CTL responses compared to HBcAg-DNA to the dominant CTL
epitope on the HBcAg in B6 mice, namely HBc93-100. CTL
specific for HBc13-23, presumably due to crossreactivity with
the WHcAg-specific CTL epitope at the WHc13-23 site, were
also produced. Because a dominant CD4+ Th cell site in B6
Figure 8. Anti-PreS1 Abs prevent acute infection and clear serum HBV from chronically infected human-liver chimeric mice. Wildtype B10 mice were immunized and
boosted with a mixture of PreS1-WHc VLPs-1.2, −1.3 and −1.6 (20 μg each) and 5 weeks after the boost sera was collected, pooled and used for the adoptive transfer.
0.2 ml of anti-PreS1-WHc sera or control anti-WHc sera were transferred into human-liver chimeric mice prior to infection with 1 × 106 GE copies of HBV/mouse in the
control and acute groups. For the chronic group, 0.2 ml of anti-VLP sera was transferred 2 and 5 weeks after the HBV infection. (a). Serum HBV-DNA was determined
at the indicated time points post-infection, (b). Liver HBV-DNA was determined at termination. The difference between the Control and Chronic groups were not
statistically significant at α = 0.05 (Wilcoxon Two-Sample Test). (c). Liver immunohistology staining for HBsAg. The scale bar is 200um.
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mice (aa120-140) is highly conserved (19 of 21aa) between
WHcAg and HBcAg, it was not surprising that the WHcAg and
HBcAg 120–140 peptides recalled a strong IFNγ response after
immunization with all three DNA constructs. However, the
H120-140 Th epitope is not functional in HBV-Tg mice due to
immune tolerance (see Figure 6). Note that IFNγ responses to the
WHcAg-specific Th epitopes WHc60-80 and WHc80-95 were
primed by the VLP-347 and hybrid WHc188/HBc149 DNAs, but
not by HBc DNA immunization. Therefore, in HBV-Tgmice, it is
anticipated that these “heterospecific”,WHcAg-unique T cells will
be able to replace the defective homospecific H120-140-specific
Th cells and become the dominant source of Th cells for the
induction of HBcAg-specific CTL (see Figure 2).
It is also possible to insert so-called “universal” Th cell
epitopes derived from tetanus (TT) and diphtheria (DT) tox-
oid proteins into the PreS1-WHc VLPs and the hybrid
WHcAg/HBcAg DNA constructs in order to elicit additional
heterospecific CD4+ Th cells. This would be most relevant in
HBV/HIV co-infection as TT/DT-specific memory Th cells
most likely were primed prior to HIV/HBV infections and
remain viable alternatives to provide “heterospecific” Th cell
function for HBV-specific B cells and CTL. As shown in
Figure 12, TT-immune mice (a model for TT-immunized
humans) produced early and enhanced anti-WHc Ab
responses when injected with a single dose of WHcAg-TT
VLPs via the action of TT-heterospecific Th cells.
Discussion
Immune tolerance to an infectious agent such as the HBV is not
a binary event (tolerance vs no tolerance), but rather represents
complex host-viral interactions. Because immune tolerance is
clonal, all viral antigens and their constituent epitopes are not
equally tolerogenic nor are all cell types equally susceptible to
tolerance induction. For example, the secreted HBeAg is more
tolerogenic than the cellular HBcAg,69 and one HBeAg-specific
epitope is more tolerogenic than another epitope on the same
HBeAg.70,71 Similarly, one would expect different degrees of
T cell tolerance to epitopes on the PreS1, PreS2, and HBsAg
envelope antigens because T cell recognition is distinct between
these envelope regions.55 At the cellular level, Th cells are often
more susceptible to tolerance induction than B cells or CTL.72
These phenomenon represent forms of “split tolerance”.
Immune tolerance preferentially occurs in high avidity clones
and is mediated by deletional and non-deletional mechanisms.
Therefore, low avidity T cells that have escaped deletion most
likely constitute the bulk of the T cell repertoire during chronic
HBV infection and low avidity T cells are more prone to negative
regulation (i.e., checkpoint inhibitors, regulatory T cells, meta-
bolic dysfunction, and clonal exhaustion). Other hosts and viral
factors such as age of infection, immune status, antigen load,
secreted or cytosolic antigen and phase of infection affect
immune tolerance as well.9,10 For vaccine immunotherapy to
be effective it must target either non-tolerant clones or non-
deleted clones in which tolerance can be reversed or circum-
vented. Therefore, we targeted PreS1-specific B cells and
HBcAg-specific CTL effector cells and bypassed the more toler-
ant prone Th cells by substituting heterospecific, WHcAg-
specific Th cells for HBV-specific Th cells. Although B cell
defects have been defined during chronic HBV infection,6 low-
level antibodies to most viral antigens are present during the
active phases of infection often masked in immune complexes.66
Further, HBc/HBeAg-specific CTL can be detected in the per-
iphery and the liver during chronic infection,73,74 however,
Figure 9. Comparison of delivery of PreS1-WHc VLP-1.6 as a DNA plasmid or as a protein. Groups of five wild-type B6 mice were immunized i.m. with 50 µg of pVAX-
VLP-1.6 DNA by electroporation (EP) using the Clinporator device (IGEA, Italy) and boosted 1 month later or mice were immunized (i.m. with 20ug) of VLP-1.6 in IFA
and boosted with 10 g one month later. A. Detection of IFNγ-specific spot-forming cells (SFC)/106 spleen cells were determined with a commercial ELISPOT assay.
Error bars indicate standard deviation of five pooled spleens measured in triplicate. B. Ab production after the primary (1°) and the boost (2°) was determined by
ELISA of pooled sera on the panel of antigens shown. The MHC class I-restricted CD8+CTL epitopes on WHcAg (W10-25) and on HBcAg (H93-100) for B6 mice are
indicated. The other peptides are MHC class II-restricted CD4+Th cell epitopes.
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similar to B cell antibody production, CTL function is subopti-
mal and not sufficient to mediate viral clearance. It is anticipated
that both of these nascent effector pathways can be enhanced by
providing more efficient Th cell function using the WHcAg
platform to present neutralizing, PreS1-specific B cell epitopes
and HBcAg-specific CTL epitopes.
Accomplishments of the current study include:
(1) Defined eight PreS1 B cell epitopes (highly con-
served amongst HBV genotypes).
(2) Inserted each of the eight PreS1 B cell epitopes onto
WHcAg carrier VLPs.
(3) Consolidated all eight PreS1 epitopes onto two
PreS1-WHc VLPs (VLP-1.6 and VLP-1.9).
(4) Demonstrated that PreS1-WHc VLPs elicited PreS1-
specific Ab that recognizes native HBV virions and
multiple L/M/S-HBsAg particles of both major ser-
otypes (ad/ay).
(5) Demonstrated that six PreS1-WHc VLPs elicited nAbs
specific for N-terminal, central and C-terminal B cell
domains of the PreS1 region, however, the central B cell
domain elicited superior neutralizing Ab. A previous
study of PreS1-HBc VLPs concluded that anti-PreS1
Abs specific for the N- and C-terminus were not viral
neutralizing.61 This suggests that the fine specificity of the
B cell response to the PreS1 region is variable and can be
influenced by the choice of HBcAg or WHcAg carrier.
(6) Demonstrated that PreS1-WHc VLPs circumvented
immune tolerance and elicited equivalent levels of
nAb to the PreS1 region in wildtype, HBV-Tg, HBc/
HBeAg-Tg, and PreS1-Tg mice lineages.
(7) Demonstrated that PreS1-WHc VLPs primed cross-
reactive, HBcAg-specific CD4+/CD8+ T cells as well
as WHcAg-heterospecific CD4+/CD8+ T cells.
(8) Demonstrated that in human-liver chimeric mice
passive transfer of PreS1 nAbs prevented an acute
HBV infection.
Figure 10. Production of hybrid WHcAg/HBcAg VLPs. (a). Full-length WHcAg188 and truncated HBcAg149 genes were co-expressed in E. coli. The mixed dimer band
was excised from the gel which was run under partially-reducing conditions and then fully reduced and run on a second gel (arrows). (b). The HBcAg149 gene was
fused to the WHcAg188 gene with a flexible linker to form a “single-chain dimer” expressed as a single open reading frame in E. coli. Purified VLPs were analyzed in
capture ELISAs specific for hybrid WHcAg/HBcAg VLPs and incapable of detecting homologous WHcAg or HBcAg VLPs. Molecular Weight Marker (MW Marker) is
Thermo Scientific PAGE Ruler with manufacturer’s kilodalton size estimates for this gel chemistry.
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(9) Demonstrated that in human-liver chimeric mice
previously infected with HBV (model of chronic
infection), PreS1 nAbs cleared serum HBV and
may arrest HBV spread in the liver possibly redu-
cing cccDNA levels.16
(10) Produced hybrid WHcAg/HBcAg particles as DNA
constructs, which elicited HBcAg-specific CD8+
CTL.
The relative scarcity of PreS1 antigen relative to the major
HBsAg is a limiting factor for anti-PreS1 nAb production
during a natural HBV infection. The capacity of the highly
immunogenic WHcAg carrier to display multiple PreS1 neu-
tralizing B cell epitopes overcomes this limitation. For exam-
ple, 240 copies of each of the eight PreS1 B cell epitopes are
displayed per PreS1-WHc VLP. A combined PreS1-WHc
VLP-1.6/VLP-1.9 vaccine formulated in an adjuvant suitable
for human use given in a prime/boost protocol with an
optimized WHcAg/HBcAg DNA construct would represent
a strong candidate therapeutic HBV vaccine. This vaccine
would be capable of circumventing immune tolerance and
eliciting multiple PreS1 nAb specificities as well as HBcAg-
specific CD8+ CTL to target intracellular HBV DNA including
cccDNA. Although a PreS1-WHc VLP prime – hybrid
WHcAg/HBcAg DNA boost regimen could be given as
a monotherapy, combination with an antiviral agent would
enhance efficacy by reducing viral load. Inserting multiple
neutralizing B cell PreS1 epitopes will mitigate the possibility
of nAb escape mutants, which may be problematic when
treating an established HBV infection. Bacterial production
of PreS1-WHc VLPs together with a WHcAg/HBcAg DNA
immunogen would be cost-efficient and compatible with any
antiviral treatment for maximum efficacy. The ultimate goal is
to produce both PreS1-WHc VLPs and WHcAg-HBcAg
hybrid VLP DNA constructs for the dual purposes of eliciting
PreS1-specific nAbs and HBcAg-specific CTL. The current
study was limited primarily to evaluating the PreS1-specific
humoral response in immune tolerant HBV-Tg mice and in
human-liver chimeric mice infected with HBV. Future studies
will be necessary to evaluate the ability of the WHcAg-HBcAg
hybrid DNA constructs produced herein to circumvent
HBcAg-specific CTL immune tolerance.
Although therapeutic HBV vaccines have not been success-
ful to date, a number of experimental vaccines show promise
in animal models or in the clinic,74,75 especially PreS-
containing candidates.76,77 However, most experimental vac-
cines rely exclusively on the use of HBV-derived antigens,
subject to the direct and indirect effects of immune tolerance,
unlike the current PreS1-WHc VLP technology. An alterna-
tive approach for bypassing immune tolerant, dysfunctional
endogenous T cells is the adoptive transfer of “engineered”
HBV-specific T cells, which are demonstrating efficacy in
animal models and in one clinical trial.78–80 In a recent
study, a single adoptive transfer of transfected HBV-specific
T cells demonstrated effective reduction in HBV DNA with-
out severe liver disease in an animal model. However, achiev-
ing long-term control of HBV infection required the
combined use of the PreS1 peptide viral entry-inhibitor
Myrcludex B.16,78 We argue that regardless of the efficacy of
any and all antiviral therapies, the induction of nAbs should
be included to prevent the spread of HBV to uninfected
hepatocytes, which may indeed be a requirement for the
complete cure of CHB infection.
In addition to use as a therapeutic HBV vaccine, other pos-
sible applications for PreS1-WHc VLPs include: Use as
a preventative vaccine in low-to-nonresponders to the
Figure 11. Hybrid WHcAg/HBcAg VLP DNA constructs can prime efficient HBcAg-specific CTL. Groups of three wild-type B6 mice were immunized with DNA
constructs (100 µg, two doses, s.c.) encoding VLP-347, WHcAg188/HBcAg149 or HBcAg alone. Splenic CTL or Th cell (5x10
5) IFNγ responses recalled by the panel of
peptides corresponding to CTL or Th epitopes and whole protein antigens are shown. HBcAg-specific CTL (†) and WHcAg-”heterospecific” Th cell (‡) responses are
highlighted. IFNγ was measured in 4-day culture supernatants by two-site ELISA. Data represent the mean ± standard deviation of 3 mice/group. Control spleen cells
from unimmunized mice cultured with antigens or DNA immunized mice cultured with media alone served as negative controls.
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conventional HBsAg vaccine; vaccination of pregnant HBV+
carrier mothers in order to provide passive transfer of PreS1-
specific neutralizing Abs to block transmission during and after
birth; an immunotherapy for chronic HDV infection; and prior
to immunosuppressive therapy, vaccination of HBV+ liver trans-
plant recipients in order to prevent infection of the new liver.
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